BioTime has received US$43 million (€37 million) from Juvenescence for a stake in AgeX and plans to spin the cell therapy subsidiary out in September. In April 2017, Californian late-stage biotech BioTime formed the subsidiary AgeX therapeutics to focus on its human aging candidates derived from regenerative stem cells. Earlier this year, fellow aging-focused firm Juvenescence made a $5 million investment in the subsidiary, and this week has upped its stake by 14.4 million shares paying BioTime $21.6 million in…